ContraFect Corp. sell me8
Zusammenfassung
Diese Einschätzung wird gerade geschlossen. Die SELL Einschätzung von me8 notiert unverändert vom Startkurs. Diese Einschätzung von me8 ist reine Spekulation, sie zählt nicht für die Renditestatistiken.ContraFect (WKN A2PZKK), a clinical-stage biotechnology firm headquartered in Yonkers, New York, specializes in developing innovative biotherapeutic drugs for patients suffering from drug-resistant and life-threatening infectious diseases. Notably, the company's primary focus revolves around leveraging lysins and amurins, a novel class of protein therapies derived from bacteriophages, to target bacterial infections. With ContraFect's commitment to advancing its therapeutic candidates through rigorous clinical trials, the company aims to fill the void left by conventional antibiotics and bring much-needed relief to patients worldwide. Trading on the NASDAQ stock exchange under the ticker symbol "CFRX," ContraFect continues to break new ground by bolstering its intellectual property portfolio and fostering strategic partnerships, creating additional value for its shareholders in the process.
Rendite ohne Dividenden (%)
| Name | 1W | 1M | 1J |
|---|---|---|---|
| ContraFect Corp. | - | - | - |
| iShares Core DAX® | 0,48 % | -0,04 % | 13,34 % |
| iShares Nasdaq 100 | 1,29 % | 0,50 % | 40,10 % |
| iShares Nikkei 225® | 1,30 % | -2,13 % | 19,86 % |
| iShares S&P 500 | 0,83 % | 0,19 % | 29,76 % |
Kommentare von me8 zu dieser Einschätzung
In der Diskussion Contrafect Corp. diskutieren
In der Diskussion Trading ContraFect Corp.